Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.
Red Light Holland submits a new patent application for its microdosing kits.
Wesana announces a strategic review of its assets and a decision to focus on drug development.
Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now